Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

Basit Öğe Kaydı
dc.contributor.authorEkici, Berkay
dc.contributor.authorYaman, Mehmet
dc.contributor.authorKucuk, Murathan
dc.contributor.authorDereli, Seckin
dc.contributor.authorYenercag, Mustafa
dc.contributor.authorYigit, Zerrin
dc.contributor.authorZoghi, Mehdi
dc.date.accessioned2021-11-01T15:06:16Z
dc.date.available2021-11-01T15:06:16Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractObjective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. Results: N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi. Conclusion: The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.
dc.identifier.doi10.5543/tkda.2021.63099
dc.identifier.endpage+en_US
dc.identifier.issn1016-5169
dc.identifier.issue5en_US
dc.identifier.pmid34308869
dc.identifier.scopus2-s2.0-85110343014
dc.identifier.scopusqualityQ3
dc.identifier.startpage357en_US
dc.identifier.urihttps://doi.org/10.5543/tkda.2021.63099
dc.identifier.urihttps://hdl.handle.net/11491/7532
dc.identifier.volume49en_US
dc.identifier.wosWOS:000672534200004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherTurkish Soc Cardiology
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi-Archives Of The Turkish Society Of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAngiotensin receptor neprilysin inhibitoren_US
dc.subjectheart failure with reduced ejection fractionen_US
dc.subjectsacubitrilen_US
dc.subjectvalsartanen_US
dc.subjectreal-worlden_US
dc.titleAngiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu